| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.53▼ | 2.55▼ | 2.56▼ | 2.87▼ | 3.52▼ |
| MA10 | 2.54▼ | 2.60▼ | 2.65▼ | 3.19▼ | 4.38▼ |
| MA20 | 2.57▼ | 2.74▼ | 2.81▼ | 3.68▼ | 5.54▼ |
| MA50 | 2.69▼ | 2.87▼ | 2.97▼ | 4.73▼ | 7.02▼ |
| MA100 | 2.82▼ | 3.09▼ | 3.49▼ | 5.76▼ | N/A |
| MA200 | 2.90▼ | 3.62▼ | 4.07▼ | 6.68▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.004▲ | -0.019▼ | -0.025▼ | -0.065▼ | -0.320▼ |
| RSI | 30.735▼ | 25.335▼ | 28.269▼ | 22.587▼ | 23.833▼ |
| STOCH | 27.418 | 3.776▼ | 2.655▼ | 13.666▼ | 3.691▼ |
| WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -99.000▼ | -99.631▼ |
| CCI | -91.119 | -101.277▼ | -101.975▼ | -103.769▼ | -137.330▼ |
|
Monday, March 09, 2026 07:17 AM
Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in difficult-to-treat cancersMechanisms of action support enhanced activity of GSK-3β plus RAS ...
|
|
Wednesday, March 04, 2026 02:30 PM
Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat ...
|
|
Tuesday, February 24, 2026 12:45 AM
CHICAGO and FORT WORTH, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 11/03/26 | 2.89 | 3.0489 | 2.5001 | 2.52 | 97,617 |
| 10/03/26 | 3.0207 | 3.0301 | 2.7401 | 2.84 | 49,130 |
| 09/03/26 | 2.85 | 3.1088 | 2.64 | 2.945 | 91,339 |
| 06/03/26 | 3.12 | 3.2399 | 2.86 | 2.86 | 82,977 |
| 05/03/26 | 3.04 | 3.22 | 2.90 | 3.20 | 82,571 |
| 04/03/26 | 3.15 | 3.18 | 2.7325 | 3.05 | 218,378 |
| 03/03/26 | 3.70 | 3.755 | 3.02 | 3.06 | 158,166 |
| 02/03/26 | 3.60 | 3.94 | 3.525 | 3.75 | 42,681 |
| 27/02/26 | 3.89 | 4.44 | 3.74 | 3.74 | 22,301 |
| 26/02/26 | 4.09 | 4.14 | 3.77 | 3.95 | 49,000 |
|
|
||||
|
|
||||
|
|